

(51) International Patent Classification:
C07D 211/96 (2006.01)(21) International Application Number:
PCT/US2010/031832(22) International Filing Date:
21 April 2010 (21.04.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/171,626 22 April 2009 (22.04.2009) US(71) Applicant (for all designated States except US): **AXIKIN PHARMACEUTICALS, INC.** [US/US]; 10835 Road To The Cure, Suite 250, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LY, Tai, Wei** [CA/US]; 10824 Caminito Colorado, San Diego, CA 92131 (US). **POTTER, Garrett, Thomas** [US/US]; 4205 Camino Ticino, San Diego, CA 92122 (US).(74) Agents: **GEORGE, Nikolaos, C.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS

(57) Abstract: Provided herein are 2,5-disubstituted arylsulfonamide CCR3 antagonists of Formula (I), (Ia) or (II), and pharmaceutical compositions thereof: wherein X, Y, Z, and R¹ - R⁵ are as defined herein. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a CCR3-mediated disorder, disease, or condition.